Cabometyx and Opdivo show durable survival benefits in first-line advanced renal cell carcinoma

Press/Media

Period	14 Feb 2023

Media coverage

Title	Cabometyx and Opdivo show durable survival benefits in first-line advanced renal cell carcinoma
Media name/outlet	Pharma Marketletter
Country/Territory	United Kingdom
Date	14/02/23
URL	ct.moreover.com/?a=50009034198&p=1gw&v=1&x=1OUXhdgVMDl96TwbmZWLCw
Persons	Mauricio Burotto